The latest price target for Gossamer Bio (NASDAQ:GOSS) was reported by HC Wainwright & Co. on June 25, 2026. The analyst firm set a price target for $2.00 expecting GOSS to rise to within 12 months (a possible 1052.07% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Gossamer Bio (NASDAQ:GOSS) was provided by HC Wainwright & Co., and Gossamer Bio maintained their buy rating.

The last upgrade for Gossamer Bio Inc happened on September 10, 2025 when UBS raised their price target to $9. UBS previously had a neutral for Gossamer Bio Inc.

The last downgrade for Gossamer Bio Inc happened on March 23, 2026 when Cantor Fitzgerald changed their price target from N/A to N/A for Gossamer Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on June 25, 2026 so you should expect the next rating to be made available sometime around June 25, 2027.

While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a maintained with a price target of $5.00 to $2.00. The current price Gossamer Bio (GOSS) is trading at is $0.17, which is out of the analyst’s predicted range.